Two Drugs, One Gap: The Race to Fill the Missing Gout Treatment Tier

Imagine your knees ache so badly that walking across a room feels like a negotiation. That is gout — the most common form of inflammatory arthritis, caused by excess uric acid crystallizing in joints. First-line treatment is allopurinol, a cheap generic that works for many patients. But for the estimated 2 million Americans who cannot tolerate it or for whom it fails, there has been no approved oral alternative. The only other option is a quarterly infusion of an enzyme that breaks down uric acid, expensive and reserved for the most severe cases. Between a daily pill and a clinic infusion, there is a clinical void — and two companies are now racing to fill it.

Crystalys Therapeutics, a San Diego biotech co-founded by Catalys Pacific and Novo Holdings, is running Phase 3 trials of dotinurad, a once-daily pill that lowers uric acid by blocking a kidney transporter protein called URAT1. Swedish Orphan Biovitrum, known as Sobi, is running its own Phase 3 program for pozdeutinurad, an oral URAT1 inhibitor acquired from Arthrosi Therapeutics in February 2026. Sobi reported its Phase 3 results in May 2026. Crystalys has not yet published Phase 3 data — its Phase 2 AMETHYST trial in roughly 90 patients with difficult-to-treat gout dosed its first patients in late 2025 — but its Phase 3 RUBY trial is enrolling approximately 500 patients and its TOPAZ trial roughly 250 patients with tophaceous gout, according to Clinical Trials Arena. Neither company has filed with the FDA.

The data in hand are strikingly similar. Sobi's REDUCE 2 trial enrolled 811 patients globally, most inadequate responders to existing uric-acid-lowering therapies. At 24 weeks, 56.6% of patients on 50 milligrams of pozdeutinurad achieved a target uric acid level below 6 milligrams per deciliter, compared with 8.1% on placebo. The 75-milligram dose did better: 69.2% hit the target, according to Sobi's press release. Both of Sobi's Phase 3 trials — REDUCE 1 and REDUCE 2 — are registered on ClinicalTrials.gov under NCT06439602 and NCT07089875, respectively. Crystalys's RUBY trial (NCT07089875) is measuring the same thing in the same patient population at the same timepoint: the proportion of patients whose serum uric acid falls below 6 mg/dL at 24 weeks.

That structural similarity is the heart of the story. URAT1 inhibitors are not new — the first-generation version, lesinurad, was approved in 2015 and later withdrawn from the US market after the FDA flagged kidney safety risks, including serious kidney adverse events in patients taking the drug as part of combination therapy. The agency's concern was specific: patients on lesinurad plus xanthine oxidase inhibitors showed elevated rates of kidney dysfunction compared to those on xanthine oxidase inhibitors alone. That safety failure ended lesinurad's commercial run in the US and created the precise regulatory problem next-generation URAT1 inhibitors are trying to solve.

Dotinurad was designed as that next generation, engineered to reduce the kidney safety signals that ended lesinurad's run. It is already approved in Japan, China, the Philippines, Taiwan, and Thailand, where Fuji Yakuhin, its inventor, navigated local regulatory review independently. Pozdeutinurad comes from Arthrosi's program, acquired by Sobi in February 2026, and has no prior US regulatory record at all — meaning REDUCE 1 and REDUCE 2 constitute its entire evidence base for a potential FDA submission.

Neither company has published a head-to-head comparison. Both are measured against placebo, not each other. And the endpoint both trials share — sUA lowering at 24 weeks — was effectively dictated by the FDA's standard expectations for this drug class, not independently invented by either sponsor. That means the data package either company brings to the FDA will answer the same question in the same way: does this drug lower uric acid in patients who have failed first-line therapy? Neither dataset will directly answer whether dotinurad is safer or more effective than pozdeutinurad.

The treatment gap is real. There is no suitable second-line oral option between allopurinol and uricase therapy in the US or EU, according to Crystalys's own science page. The gap affects patients who cycle through allopurinol, hit its limits, and face either off-label drug combinations or a quarterly infusion. Filling it is a legitimate unmet need, and both companies are genuinely trying to fill it. The question is whether the gap has room for two entrants close enough in profile that commercial execution — pricing, salesforce, formulary placement — becomes the real competitive battleground.

Sobi expects to read out REDUCE 1, its second Phase 3 trial, in the second half of 2026, according to its press release. Crystalys has not announced specific RUBY or TOPAZ readout dates, only estimated completion windows of 64 and 76 weeks respectively. If both programs stay on track, the FDA could receive two applications for the same indication, from the same drug class, within the same review cycle. Regulators prefer clear differentiation between competing drugs in the same class — when that differentiation is clinical, the approval calculus is straightforward. When it is commercial, the agency has less to work with, and the commercial winner may simply be whoever gets there first or negotiates a better market position.

The race is real. The differentiation may not be.